BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12240550)

  • 1. Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
    Stranzl H; Gabor S; Mayer R; Prettenhofer U; Wurzinger G; Hackl A
    Strahlenther Onkol; 2002 Aug; 178(8):442-5. PubMed ID: 12240550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.
    Chang LF; Horvath J; Peyton W; Ling SS
    Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):589-96. PubMed ID: 7509330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose endobronchial brachytherapy in malignant tumors of the lung].
    Escobar Sacristán J; de Granda Orive JI; Gutiérrez Jiménez T; Martínez Albiach JM; Fuentes Ramos M; Herrera de la Rosa A
    Arch Bronconeumol; 1997 Jun; 33(6):278-83. PubMed ID: 9289322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies.
    Gustafson G; Vicini F; Freedman L; Johnston E; Edmundson G; Sherman S; Pursel S; Komic M; Chen P; Borrego JC
    Cancer; 1995 May; 75(9):2345-50. PubMed ID: 7712446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Endoluminal HDR brachytherapy in the palliative treatment of patients with the recurrence of a non-small-cell bronchial carcinoma after prior radiotherapy].
    Micke O; Prott FJ; Schäfer U; Wagner W; Pötter R; Willich N
    Strahlenther Onkol; 1995 Oct; 171(10):554-9. PubMed ID: 8571174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors.
    Niemoeller OM; Pöllinger B; Niyazi M; Corradini S; Manapov F; Belka C; Huber RM
    Radiat Oncol; 2013 Jan; 8():8. PubMed ID: 23289530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer.
    Mattiucci GC; Autorino R; Tringali A; Perri V; Balducci M; Deodato F; Gambacorta MA; Mantini G; Tagliaferri L; Mutignani M; Morganti AG
    Brachytherapy; 2015; 14(3):401-4. PubMed ID: 25591935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.
    Ozkok S; Karakoyun-Celik O; Goksel T; Mogulkoc N; Yalman D; Gok G; Bolukbasi Y
    Lung Cancer; 2008 Dec; 62(3):326-33. PubMed ID: 18482780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma.
    Corner C; Bryant L; Chapman C; Glynne-Jones R; Hoskin PJ
    Brachytherapy; 2010; 9(1):66-70. PubMed ID: 19846349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
    Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
    Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer.
    Celebioglu B; Gurkan OU; Erdogan S; Savas I; Köse K; Kurtman C; Gonullu U
    Jpn J Clin Oncol; 2002 Nov; 32(11):443-8. PubMed ID: 12499415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions.
    Delclos ME; Komaki R; Morice RC; Allen PK; Davis M; Garden A
    Radiology; 1996 Oct; 201(1):279-82. PubMed ID: 8816560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma.
    Ofiara L; Roman T; Schwartzman K; Levy RD
    Chest; 1997 Oct; 112(4):946-53. PubMed ID: 9377957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma.
    Hoskin PJ; de Canha SM; Bownes P; Bryant L; Glynne Jones R
    Radiother Oncol; 2004 Nov; 73(2):195-8. PubMed ID: 15542167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endobronchial brachytherapy and external-beam radiotherapy in patients with endobronchial obstruction and extrabronchial extension.
    Gejerman G; Mullokandov EA; Bagiella E; Blaivas A; Beitler JJ
    Brachytherapy; 2002; 1(4):204-10. PubMed ID: 15062168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose-rate intraluminal irradiation in bronchogenic carcinoma. Technique and results.
    Nori D; Allison R; Kaplan B; Samala E; Osian A; Karbowitz S
    Chest; 1993 Oct; 104(4):1006-11. PubMed ID: 7691481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients.
    Gollins SW; Burt PA; Barber PV; Stout R
    Radiother Oncol; 1994 Oct; 33(1):31-40. PubMed ID: 7533304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience.
    Kelly JF; Delclos ME; Morice RC; Huaringa A; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):697-702. PubMed ID: 11020566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endobronchial brachytherapy in the treatment of malignant lung tumours.
    Escobar-Sacristán JA; Granda-Orive JI; Gutiérrez Jiménez T; Delgado JM; Rodero Baños A; Saez Valls R
    Eur Respir J; 2004 Sep; 24(3):348-52. PubMed ID: 15358689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irriadiated lung cancer.
    Kubaszewska M; Skowronek J; Chicheł A; Kanikowski M
    Neoplasma; 2008; 55(3):239-45. PubMed ID: 18348661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.